Want to see CBIO full AI Analyst Report?

Crescent Biopharma (CBIO) Price & Analysis

1,025 Followers

CBIO Stock Chart & Stats

$21.28

Market closed

$21.28

Day’s Range― - ―

52-Week Range$8.72 - $27.41

Previous CloseN/A

VolumeN/A

Average Volume (3M)145.41K

Market Cap

$526.08M

Enterprise Value$374.79

Total Cash (Recent Filing)$189.16M

Total Debt (Recent Filing)$1.54M

Price to Earnings (P/E)―

Beta1.16

Next Earnings

Jul 30, 2026

EPS Estimate

-0.74

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.91

Shares Outstanding35,666,730

10 Day Avg. Volume163,515

30 Day Avg. Volume145,412

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.61

Price to Sales (P/S)11.39

P/FCF Ratio-1.70

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$31.00

Price Target Upside45.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-3.2

Revenue Forecast (FY)$1.82M

Bulls Say, Bears Say

Bulls Say

Revenue Growth TrendSustained, large revenue improvement signals meaningful commercial traction and market adoption versus prior year. This durable top-line expansion can increase operating leverage as fixed costs are spread, improving the path to break-even if growth continues and execution remains consistent.

Very High Gross MarginAn exceptionally high gross margin indicates strong unit economics and low cost of goods sold relative to revenue. Over the medium term this supports scalability and long-term profitability once operating expenditures normalize, reducing capital intensity per incremental dollar of revenue.

Low Leverage / Balance-Sheet FlexibilityVery low leverage provides durable financial flexibility: lower default and covenant risk, more optionality for strategic R&D or commercialization investments, and cleaner access to capital markets if needed, which is particularly valuable for a development-stage biotech with variable cash needs.

Bears Say

Large Ongoing LossesDeep, persistent operating losses show current revenues are far from covering operating costs. This structural profitability gap risks equity erosion and forces management to focus on financing and cost control rather than long-term growth initiatives until margins move materially toward breakeven.

Negative Operating And Free Cash FlowSustained negative operating and free cash flow creates ongoing funding needs. Even with improvement versus prior year, continued cash burn elevates the risk of dilution or constrained investment in commercialization and R&D, making liquidity and financing strategy central medium-term risks.

Persistently Negative Returns On EquityA very negative ROE indicates the company is destroying shareholder capital on current operations. Until returns flip positive, investor confidence and the ability to attract non-dilutive capital may be impaired, and management must demonstrate sustained profitability improvements to reverse this structural weakness.

Crescent Biopharma News

Crescent Biopharma 8.095M share Spot Secondary priced at $14.50

Jefferies, TD Cowen, Guggenheim and Cantor Fitzgerald acted as joint book running managers for the offering. Published first...

5d ago

CBIO

Crescent Biopharma files ordinary shares offering, no amount given

Jefferies, TD Cowen, Guggenheim, and Cantor are acting as joint book-running managers. LifeSci Capital is acting as a...

6d ago

CBIO

BTIG says others may be interested in Apogee Therapeutics

BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis...

28d ago

JNJ

NVS

Campbell, Crescent, Cardiff, Sherwin, Take-Two Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CPB) ), ( ($CBIO) ), ( ($CRDF) ), ( ($SHW)...

1M ago

CPB

SHW

Crescent Biopharma shareholders back directors, pay and auditor

Crescent Biopharma ( ($CBIO) ) just unveiled an update. On June 2, 2026, Crescent Biopharma, Inc. held its...

2M ago

CBIO

Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Crescent Biopharma (CBIO) to Neutral from Buy without a price target saying the ivonescimab copycat...

2M ago

CBIO

Crescent Biopharma reports Q1 EPS (70c), consensus (79c)

Reports Q1 revenue $1.04M, consensus $357,140. “Crescent’s execution on the advancement of our pipeline this quarter positions us...

3M ago

CBIO

Crescent Biopharma management to meet with Cantor Fitzgerald

Meeting to be held in San Francisco on April 14, in Denver on April 15 and in New...

3M ago

CBIO

Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Crescent Biopharma (CBIO) to $22 from $25 and keeps a...

5M ago

CBIO

Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year

Reports Q4 revenue $10.8M vs .$0 last year. “2025 was a transformational year for Crescent and our efforts...

5M ago

CBIO

Crescent Biopharma sees cash runway into 2028

Cash and cash equivalents were $213.2 million as of December 31, 2025, which is anticipated to fund operations...

5M ago

CBIO

3 ‘Strong Buy’ Stocks to Buy Now, 2/19/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

5M ago

CBIO

CHWY

Crescent Biopharma announces grants of inducement awards

Crescent Biopharma (CBIO) announced that the independent Compensation Committee of its Board of Directors approved the grant of...

5M ago

CBIO

Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Crescent Biopharma today and set a price target...

5M ago

CBIO

CBIO FAQ

What was Crescent Biopharma’s price range in the past 12 months?

Crescent Biopharma lowest stock price was $8.72 and its highest was $27.41 in the past 12 months.

What is Crescent Biopharma’s market cap?

Crescent Biopharma’s market cap is $526.08M.

When is Crescent Biopharma’s upcoming earnings report date?

Crescent Biopharma’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.

How were Crescent Biopharma’s earnings last quarter?

Crescent Biopharma released its earnings results on Apr 29, 2026. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.879 by $0.179.

Is Crescent Biopharma overvalued?

According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Crescent Biopharma pay dividends?

Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here

What is Crescent Biopharma’s EPS estimate?

Crescent Biopharma’s EPS estimate is -0.74.

How many shares outstanding does Crescent Biopharma have?

Crescent Biopharma has 35,666,730 shares outstanding.

What happened to Crescent Biopharma’s price movement after its last earnings report?

Crescent Biopharma reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.879. Following the earnings report the stock price went up 6.829%.

Which hedge fund is a major shareholder of Crescent Biopharma?

Currently, no hedge funds are holding shares in CBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Crescent Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

3223.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Crescent Biopharma

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Crescent Biopharma (CBIO) Earnings & Revenues

Historic Earnings Reports

CBIO Stock 12 Month Forecast

Average Price Target

$31.00

▲(45.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","15":"$15","22":"$22","29":"$29","36":"$36"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15,22,29,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.08,18.45846153846154,19.836923076923075,21.215384615384615,22.59384615384615,23.97230769230769,25.35076923076923,26.729230769230767,28.107692307692307,29.486153846153847,30.864615384615384,32.24307692307693,33.621538461538464,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.08,18.150769230769228,19.22153846153846,20.29230769230769,21.36307692307692,22.433846153846154,23.504615384615384,24.575384615384614,25.646153846153844,26.716923076923077,27.787692307692307,28.85846153846154,29.92923076923077,{"y":31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.08,17.84307692307692,18.606153846153845,19.369230769230768,20.13230769230769,20.895384615384614,21.658461538461538,22.42153846153846,23.184615384615384,23.947692307692307,24.71076923076923,25.473846153846154,26.236923076923077,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.82,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.07,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.72,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.08,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >